CSO Speaks at National Research Meeting

AI SummaryClose X

Solvonis Therapeutics plc announced that its Chief Scientific Officer, Professor David Nutt, will speak at a U.S. National Institutes of Health addiction research meeting on May 6, 2026, discussing psychedelic therapy for addictions. This participation highlights the company's scientific leadership and the relevance of its CNS disorder pipeline, which includes late-stage programs like SVN-001 for Alcohol Use Disorder and a preclinical program for stimulant-use disorders selected by the U.S. National Institute on Drug Abuse. The NIH, a significant funder of biomedical research with an annual budget exceeding $47 billion, and its constituent institutes like NIDA (FY2025 budget request of approximately $1.67 billion) and NIAAA (FY2025 appropriation of approximately $595 million), are key players in shaping addiction research priorities globally.

Disclaimer*

UK 100

Latest directors dealings